Evaluation of Intranasal TLR2/6 agonist INNA-051: Safety, Tolerability and Proof of Pharmacology
Open Access
- 13 June 2024
- journal article
- research article
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 10 (6)
Abstract
Background: Local priming of the innate immune system with a TLR2/6 agonist may reduce morbidity and mortality associated with viral respiratory tract infections, particularly for the elderly and those with chronic diseases.Objectives: To understand the potential of prophylactic treatment with a TLR2/6 agonist as an enhancer of innate immunity pathways leading to accelerated respiratory virus clearance from the upper airways.Methods: Two randomized, double-blind, placebo-controlled clinical trials were conducted in healthy adult participants. The first dose-escalation study assessed safety, tolerability and mechanistic biomarkers following single and repeated intranasal administrations of INNA-051. The second was an Influenza A viral challenge study assessing the impact of treatment on host defence biomarkers and viral load.Results: INNA-051 was well tolerated in both studies, with no dose-limiting toxicities identified. Mechanistic biomarkers assessed in both studies demonstrated the expected engagement of pharmacology, including innate immune pathways. There were lower than anticipated rates of infection. Post hoc analysis conducted in laboratory-confirmed infected participants with low or no antibody titre against the challenge virus showed INNA-051 treatment led to significantly shorter duration of infection and increased expression of genes and pathways associated with host defence responses against influenza.Conclusions: The safety and pharmacology profile of INNA-051 confirms preclinical studies. INNA-051 increased expression of genes and pathways associated with host defence responses against influenza and was associated with shorter duration of infection. These studies support further clinical assessment in the context of natural viral respiratory tract infections in individuals at increased risk of severe illness.Keywords
This publication has 68 references indexed in Scilit:
- Intranasal Treatment with Poly(I·C) Protects Aged Mice from Lethal Respiratory Virus InfectionsJournal of Virology, 2012
- Intranasal Administration of the TLR2 Agonist Pam2Cys Provides Rapid Protection against Influenza in MiceMolecular Pharmaceutics, 2012
- Transcription Factor Redundancy Ensures Induction of the Antiviral StateJournal of Biological Chemistry, 2010
- Permissive Secondary Mutations Enable the Evolution of Influenza Oseltamivir ResistanceScience, 2010
- The role of pattern-recognition receptors in innate immunity: update on Toll-like receptorsNature Immunology, 2010
- Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligandsNature Immunology, 2009
- Activation of toll-like receptor signaling pathway for protection against influenza virus infectionVaccine, 2009
- Neuraminidase inhibitor resistance in influenza virusesJournal of Medical Virology, 2007
- A novel method for prokaryotic promoter prediction based on DNA stabilityBMC Bioinformatics, 2005
- The impact of influenza epidemics on mortality: introducing a severity index.American Journal of Public Health, 1997